The U.S. Food and Drug Administration recently held its first public comments session on CBD and CBD-infused products, though it appears the agency is not any closer to regulating what is formally known as cannabidiol, the non-psychoactive ingredient often associated with cannabis.

“As far as the markets and the proponents of the CBD, the same is being said over and over,” said Jean Gonnell, general counsel of STWC Holdings Inc. “Regulation and guidance is needed.”